This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Setipiprant

Allergan plc

Drug Names(s): ACT-129968, CRTH2 Antagonist, Actelion-8, KYTH-105

Description: ACT-129968 is an oral antagonist of chemoattractant receptor-homologous molecule expressed on T helper type 2 lymphocytes (CRTH2). CRTH2 is a cognate receptor for prostaglandin (PG) D2 and, in humans, is suggested to play a functional role in Th2-dependent allergic inflammation.

Deal Structure: Kythera and Actelion
In February 2015, Kythera Biopharmaceuticals announced that it has entered into separate license agreements with Actelion Pharmaceuticals and the University of Pennsylvania for a novel approach for the treatment of hair loss. Under the terms of the agreement with Actelion, Kythera Holdings licensed the worldwide rights to setipiprant. As part of the agreement, Actelion will be eligible to receive up to $27 million in potential development and regulatory milestones, as well as royalties on sales if setipiprant is successfully commercialized.

Kythera and University of Pennsylvania
In February 2015, Kythera Biopharmaceuticals announced that it has entered into separate license agreements with Actelion Pharmaceuticals and the University of Pennsylvania for a novel approach for the treatment of hair loss. Under the terms of the agreement with the University of Pennsylvania, Kythera Holdings acquired exclusive worldwide rights to certain...See full deal structure in Biomedtracker

Partners: Actelion Pharmaceuticals Ltd. University of Pennsylvania


Setipiprant News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug